Conmed (CNMD) Misses Q2 EPS by 8c, Maintains FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Northland Capital Markets Downgrades CONMED (CNMD) to Market Perform
July 22, 2015 7:19 AM EDTNorthland Capital Markets downgraded CONMED (NASDAQ: CNMD) from Outperform to Market Perform with a price target of $58.00 (from $65.00), saying 2nd-half guidance may be too optimistic.
Analyst Mark Landy commented, "CNMD reported in line 2Q revenues of $181M but missed our and the... More
Needham & Company Raises Price Target to $60 Following Conmed's (CNMD) 2Q Miss
July 22, 2015 6:58 AM EDTNeedham & Company reiterated a Buy rating on CONMED (NASDAQ: CNMD), and raised the price target to $60.00 (from $56.00), following 2Q15. CNMD's reported revenue was $181.0M vs. consensus of $182.3M. EPS was $0.36 vs. consensus of $0.44. Analyst Mike Matson said that investors may give management the benefit of... More
